

**In the Specification:**

Please replace the specification filed on March 21, 2002 with the amended application submitted herewith in Appendix B.

**In the Claims:**

Please amend claims 1-9 to read as follows:

Sub  
OC1  
1) A method for lowering the chemotherapy-induced resistance in a patient being treated with a chemotherapeutic agent for a cancer, the method comprising: infecting the patient with an effective amount of AAV-2 to lower the chemotherapy-induced resistance to the chemotherapeutic agent, in combination with administering a chemotherapeutic agent.

B1  
2) The method according to claim 1, wherein the AAV-2 is used in a dose of  $10^9$  -  $10^{10}$  AAV particles/kg body weight.

3) The method according to claim 1 wherein the chemotherapeutic agent is selected from the group consisting of: cisplatin, etoposide and cisplatin/etoposide.

4) The method according to any of claims 1 to 3, wherein the cancer to be treated by chemotherapy is a colon cancer, pancreatic carcinoma or brain tumor or small cell lung carcinoma.

Sub  
OC2  
5) The method according to any of claims 1 to 4, wherein the use is made intravenously, cutaneously, orally or intratumorally.

<sup>1</sup> Consistent with requirements of 37 CFR §1.121, a marked-up version of the amended specification and claims is set out in Appendix A; a clean copy of the specification and all pending claims is set out in Appendix B.

6) The method according to any of claims 1 to 5, wherein the infecting with the AAV-2 is made before, after or simultaneously with a chemotherapy or radiotherapy.

*Sub D1*  
*B1*  
*CDN 4.* 7) A pharmaceutical composition containing a chemotherapeutic agent and an effective dose of AAV-2 to reverse chemotherapy-induced resistance in patients suffering from small cell lung carcinoma.

8) The pharmaceutical composition according to claim 7, wherein the chemotherapeutic agent is selected from the group consisting of: cisplatin, etoposide and cisplatin/etoposide.

9) The pharmaceutical composition according to claim 7 or 8, wherein the composition is formulated in a member selected from the group consisting of; an injection solution, infusion solution, an aerosol spray or an ointment.

Please add the following new claims:

*Sub SC3*  
*B2* 10) A method for reversing chemotherapy-induced resistance in a patient suffering from a small cell lung carcinoma cancer and previously treated for the cancer by a chemotherapeutic agent, the method comprising: infecting the patient with a sufficient amount of AAV-2 to reverse the chemotherapy-induced resistance to the chemotherapeutic agent in combination with administering the chemotherapeutic agent to the patient.

11) The method according to claim 10, wherein the AAV-2 is administered at a dose of  $10^9$  -  $10^{10}$  AAV particles/kg body weight.

- 12) The method according to claim 1, wherein the chemotherapeutic agent comprises an agent selected from the group consisting of: cisplatin, etoposide and cisplatin/etoposide.
-